Cargando…
Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF(V600E) Mutant Melanoma Cells
[Image: see text] Polo-like kinase 1 (Plk1) is a serine/threonine kinase that plays a key role during the cell cycle by regulating mitotic entry, progression, and exit. Plk1 is overexpressed in a variety of human cancers and is essential to sustained oncogenic proliferation, thus making Plk1 an attr...
Autores principales: | Cholewa, Brian D., Pellitteri-Hahn, Molly C., Scarlett, Cameron O., Ahmad, Nihal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227549/ https://www.ncbi.nlm.nih.gov/pubmed/24884503 http://dx.doi.org/10.1021/pr5002516 |
Ejemplares similares
-
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
por: Lin, C-C, et al.
Publicado: (2014) -
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1
por: Gohda, Jin, et al.
Publicado: (2018) -
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells
por: Chen, Er, et al.
Publicado: (2020) -
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015) -
Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach
por: Singh, Chandra K., et al.
Publicado: (2015)